News from AHA 2024: KRAKEN trial, Muvalaplin, Lp(a)

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

LDL-C Management Trends in ASCVD Patients
LDL-C Management Trends in ASCVD Patients
Heart Matters
LDL-C Management Trends in ASCVD Patients
- Keith C. Ferdinand, MD
No benefit of routine spironolactone post-MI
No benefit of routine spironolactone post-MI
Heart Matters
No benefit of routine spironolactone post-MI
- Sanjit Jolly, MD
Audit and feedback strategy for pharmacists improves HF care
Audit and feedback strategy for pharmacists improves HF care
Heart Matters
Audit and feedback strategy for pharmacists improves HF care
- Alexander Sandhu, MD
Effect of decision support system on early optimization of lipid-lowering therapy
Effect of decision support system on early optimization of lipid-lowering therapy
Heart Matters
Effect of decision support system on early optimization of lipid-lowering therapy
- Kausik Ray, MBChB, MD, MPhil

Promising results with oral Lp(a) inhibitor in phase 2 trial